Evidence map›Paper›PMID 37552495›Full record

ArticleDalton transactions (Cambridge, England : 2003)2023

Fine-tuning the cytotoxicity of ruthenium(II) arene compounds to enhance selectivity against breast cancers.

Sarah A P Pereira, Jan Romano-deGea, Ana Isabel Barbosa, Sofia A Costa Lima, Paul J Dyson, M Lúcia M F S Saraiva

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Dalton transactions (Cambridge, England : 2003), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 11 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Sarah A P PereiraLAQV, REQUIMTE, Departamento de Ciências Químicas, Faculdade de Farmácia, Universidade do Porto, Rua Jorge Viterbo Ferreira, no 228, 4050-313 Porto, Portugal. lsaraiva@ff.up.pt.
Jan Romano-deGeaInstitut des Sciences et Ingénierie Chimiques, École Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland. paul.dyson@epfl.ch.ORCID http://orcid.org/0000-0001-7340-4135
Ana Isabel BarbosaLAQV, REQUIMTE, Departamento de Ciências Químicas, Faculdade de Farmácia, Universidade do Porto, Rua Jorge Viterbo Ferreira, no 228, 4050-313 Porto, Portugal. lsaraiva@ff.up.pt.ORCID http://orcid.org/0000-0001-8690-3187
Sofia A Costa LimaLAQV, REQUIMTE, Departamento de Ciências Químicas, Faculdade de Farmácia, Universidade do Porto, Rua Jorge Viterbo Ferreira, no 228, 4050-313 Porto, Portugal. lsaraiva@ff.up.pt.
Paul J DysonInstitut des Sciences et Ingénierie Chimiques, École Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland. paul.dyson@epfl.ch.ORCID http://orcid.org/0000-0003-3117-3249
M Lúcia M F S SaraivaLAQV, REQUIMTE, Departamento de Ciências Químicas, Faculdade de Farmácia, Universidade do Porto, Rua Jorge Viterbo Ferreira, no 228, 4050-313 Porto, Portugal. lsaraiva@ff.up.pt.ORCID http://orcid.org/0000-0001-6539-1741
Universidade do Porto · PTÉcole Polytechnique Fédérale de Lausanne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ruthenium-based complexes have been suggested as promising anticancer drugs exhibiting reduced general toxicity compared to platinum-based drugs. In particular, Ru(η

Indexed as

Antineoplastic AgentsBreast NeoplasmsCoordination ComplexesOrganometallic CompoundsRutheniumCell Line, TumorFemaleHumansTolueneAntineoplastic AgentsCoordination ComplexesOrganometallic CompoundsRutheniumToluene

Identifiers

PMID37552495
PMCPMC10442743
OpenAlexW4385355565

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.